- A company is conducting clinical trials and seeking drug approval for the U.S. market under the FDA.
Shattuck Labs, Inc. announced that it submitted an IND application to the FDA, with Taylor Schreiber serving as CEO and OrbiMed leading the recent private placement.
5 reports, 2 independent
Updated Aug 11
Gone quiet
- Reports
- 5
- Developments
- 1
- Repetition
- 80%
New informationRepeats or wire copies
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Shattuck Labs, Inc. announced that it submitted an IND application to the FDA, with Taylor Schreiber serving as CEO and OrbiMed leading the recent private placement.
Who's involved
What this event is mainly aboutKeep exploring
Part of
A company is conducting clinical trials and seeking drug approval for the U.S. market under the FDA.Also in this story
- A partnership with BARDA has accelerated the development of SCY-247 for the company.
- A company plans to submit regulatory applications to the FDA, EMA, and Australian TGA.
- Approval leads to procurement process initiation.
- UroGen Pharma Ltd., headquartered in Princeton, is seeking FDA approval for its products for the U.S. market.
The entities involved
Coverage
Newest first; wire copies grouped- finanznachrichten.de
- GlobeNewswireShattuck Labs Reports Second Quarter 2025 Financial Results and Recent Business Highlights – Submitted Investigational New Drug (IND) application to evaluate SL-325 in a Phase 1 clinical trial in hea
- GlobeNewswireShattuck Labs Announces Oversubscribed Private Placement of Up to Approximately $103 Million – Aggregate net proceeds expected to fund SL-325 through multiple Phase 2 clinical trials, including in In
- Unknown outlet